{
  "id": "5c6587d77c78d69471000005",
  "type": "yesno",
  "question": "Can enasidenib be used for the treatment of acute myeloid leukemia?",
  "ideal_answer": "Yes, enasidenib has been approved for the treatment of adults with relapsed and refracctory acture myelogenous leukemia with an IDH2 mutation.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29770715"
  ],
  "snippets": [
    {
      "text": "In August 2017, the United States Federal Drug Administration (FDA) approved enasidenib (Idhifa, Celgene/Agios) for adults with relapsed and refractory acute myelogenous leukemia (AML) with an IDH2 mutation. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29770715",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}